{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:35:29Z","timestamp":1791992129821,"version":"4.4.0"},"reference-count":284,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272324"],"award-info":[{"award-number":["82272324"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82560680"],"award-info":[{"award-number":["82560680"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Shandong Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["ZR2024QH405"],"award-info":[{"award-number":["ZR2024QH405"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Therapeutic resistance remains a major obstacle to durable cancer control, with functional reprogramming of the DNA damage response (DDR) network playing a central role. The poly(ADP-ribose) polymerase (PARP) family, particularly PARP1 and PARP2, is crucial for maintaining genomic integrity. By exploiting synthetic lethality, PARP inhibitors (PARPi) selectively target tumors with homologous recombination deficiency (HRD) and are integral to precision therapy in ovarian, breast, and prostate cancers. However, over 40% of patients with BRCA1\/2 alterations develop resistance, and patient eligibility remains limited by the low prevalence of HRD mutations. In this review, we summarize the molecular mechanisms of PARPi action, resistance pathways, and emerging combination strategies. PARPi resistance arises through HR restoration (e.g., BRCA1\/2 reversion mutations), replication fork protection, RAD51-mediated strand invasion, and metabolic reprogramming. Combination therapies, integrating PARPi with histone deacetylase inhibitors, cyclin-dependent kinase inhibitors, immune checkpoint blockade, or radiation, enhance efficacy by converging on DNA repair pathways and the tumor immune microenvironment. A deeper understanding of coordinated DDR regulation and rationally designed combination regimens will be essential for overcoming PARPi resistance and advancing adaptive, precision-based therapeutic strategies.<\/jats:p>","DOI":"10.3390\/pharmaceutics18030355","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T14:46:31Z","timestamp":1773326791000},"page":"355","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Interplay Between Poly(ADP-ribosyl)ation and Specific Inner Cellular Events That Suggest Combination Strategies for Overcoming PARP Inhibitor Resistance"],"prefix":"10.3390","volume":"18","author":[{"given":"Lingwen","family":"Xu","sequence":"first","affiliation":[{"name":"Institute of Chemical Drugs, Shandong Academy of Pharmaceutical Sciences, Jinan 250101, China"},{"name":"Shandong Engineering Research Center of Pharmaceutical Green Intelligent Technology, Shandong Academy of Pharmaceutical Sciences, Jinan 250101, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Kong","sequence":"additional","affiliation":[{"name":"Institute of Chemical Drugs, Shandong Academy of Pharmaceutical Sciences, Jinan 250101, China"},{"name":"Shandong Engineering Research Center of Pharmaceutical Green Intelligent Technology, Shandong Academy of Pharmaceutical Sciences, Jinan 250101, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institute of Chemical Drugs, Shandong Academy of Pharmaceutical Sciences, Jinan 250101, China"},{"name":"Shandong Engineering Research Center of Pharmaceutical Green Intelligent Technology, Shandong Academy of Pharmaceutical Sciences, Jinan 250101, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Ma","sequence":"additional","affiliation":[{"name":"Key Laboratory of Protection, Development and Utilization of Medicinal Resources in Liupanshan Area, Ministry of Education, Ningxia Medical University, Yinchuan 750004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinzhi","family":"Li","sequence":"additional","affiliation":[{"name":"Institute of Chemical Drugs, Shandong Academy of Pharmaceutical Sciences, Jinan 250101, China"},{"name":"Shandong Engineering Research Center of Pharmaceutical Green Intelligent Technology, Shandong Academy of Pharmaceutical Sciences, Jinan 250101, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiao","family":"Deng","sequence":"additional","affiliation":[{"name":"Institute of Chemical Drugs, Shandong Academy of Pharmaceutical Sciences, Jinan 250101, China"},{"name":"Shandong Engineering Research Center of Pharmaceutical Green Intelligent Technology, Shandong Academy of Pharmaceutical Sciences, Jinan 250101, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Liu","sequence":"additional","affiliation":[{"name":"Institute of Chemical Drugs, Shandong Academy of Pharmaceutical Sciences, Jinan 250101, China"},{"name":"Shandong Engineering Research Center of Pharmaceutical Green Intelligent Technology, Shandong Academy of Pharmaceutical Sciences, Jinan 250101, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Ren","sequence":"additional","affiliation":[{"name":"Institute of Chemical Drugs, Shandong Academy of Pharmaceutical Sciences, Jinan 250101, China"},{"name":"Shandong Engineering Research Center of Pharmaceutical Green Intelligent Technology, Shandong Academy of Pharmaceutical Sciences, Jinan 250101, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Tang","sequence":"additional","affiliation":[{"name":"Institute of Chemical Drugs, Shandong Academy of Pharmaceutical Sciences, Jinan 250101, China"},{"name":"Shandong Engineering Research Center of Pharmaceutical Green Intelligent Technology, Shandong Academy of Pharmaceutical Sciences, Jinan 250101, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daizhou","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institute of Chemical Drugs, Shandong Academy of Pharmaceutical Sciences, Jinan 250101, China"},{"name":"Shandong Engineering Research Center of Pharmaceutical Green Intelligent Technology, Shandong Academy of Pharmaceutical Sciences, Jinan 250101, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s42255-021-00491-8","article-title":"The flavonoid procyanidin C1 has senotherapeutic activity and increases lifespan in mice","volume":"3","author":"Xu","year":"2021","journal-title":"Nat. Metab."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"217835","DOI":"10.1016\/j.canlet.2025.217835","article-title":"Lactylation in tumor microenvironment and immunotherapy resistance: New mechanisms and challenges","volume":"627","author":"Zhu","year":"2025","journal-title":"Cancer Lett."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/HEP.0000000000000237","article-title":"Mechanisms of drug resistance in HCC","volume":"79","author":"Ladd","year":"2024","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41580-022-00571-x","article-title":"Revolutionizing DNA repair research and cancer therapy with CRISPR-Cas screens","volume":"24","author":"Awwad","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"116663","DOI":"10.1016\/j.biopha.2024.116663","article-title":"H2AX: A key player in DNA damage response and a promising target for cancer therapy","volume":"175","author":"Prabhu","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Vern\u00ec, F. (2022). DNA Damage Response (DDR) and DNA Repair. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23137204"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41573-024-01060-w","article-title":"DNA damage response inhibitors in cancer therapy: Lessons from the past, current status and future implications","volume":"24","author":"Drew","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.bpg.2016.07.002","article-title":"The rationale of combined radiotherapy and chemotherapy\u2014Joint action of Castor and Pollux","volume":"30","author":"Brunner","year":"2016","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","article-title":"Targeting DNA damage response pathways in cancer","volume":"23","author":"Groelly","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"101287","DOI":"10.1016\/j.drup.2025.101287","article-title":"Targeting DNA damage response pathways in tumor drug resistance: Mechanisms, clinical implications, and future directions","volume":"83","author":"Zhu","year":"2025","journal-title":"Drug Resist. Updates"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13045-022-01228-0","article-title":"Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies","volume":"15","author":"Padella","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"105779","DOI":"10.1016\/j.isci.2022.105779","article-title":"Dynamics of endogenous PARP1 and PARP2 during DNA damage revealed by live-cell single-molecule imaging","volume":"26","author":"Mahadevan","year":"2022","journal-title":"iScience"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"gkaf864","DOI":"10.1093\/nar\/gkaf864","article-title":"Deciphering the dark side of histone ADP-ribosylation: What structural features of damaged nucleosome regulate the activities of PARP1 and PARP2","volume":"53","author":"Kurgina","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Nussenzweig","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5893","DOI":"10.1038\/s41467-021-26172-4","article-title":"The regulatory landscape of the human HPF1- and ARH3-dependent ADP-ribosylome","volume":"12","author":"Hendriks","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1039\/D1SC06256E","article-title":"Discovery of an NAD+ analogue with enhanced specificity for PARP1","volume":"13","author":"Zhang","year":"2022","journal-title":"Chem. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/nar\/gkaa1188","article-title":"An atypical BRCT-BRCT interaction with the XRCC1 scaffold protein compacts human DNA Ligase III\u03b1 within a flexible DNA repair complex","volume":"49","author":"Hammel","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"gkaf086","DOI":"10.1093\/nar\/gkaf086","article-title":"XRCC1 mediates PARP1- and PAR-dependent recruitment of PARP2 to DNA damage sites","volume":"53","author":"Lin","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: Synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","article-title":"Understanding and overcoming resistance to PARP inhibitors in cancer therapy","volume":"18","author":"Dias","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: The underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.annonc.2020.06.004","article-title":"The forefront of ovarian cancer therapy: Update on PARP inhibitors","volume":"31","author":"Mirza","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"108642","DOI":"10.1016\/j.pharmthera.2024.108642","article-title":"Cisplatin in the era of PARP inhibitors and immunotherapy","volume":"258","author":"Duan","year":"2024","journal-title":"Pharmacol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e70314","DOI":"10.1002\/mco2.70314","article-title":"PARP (Poly ADP-ribose Polymerase) Family in Health and Disease","volume":"6","author":"Lei","year":"2025","journal-title":"MedComm"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.sbi.2018.11.002","article-title":"PARP family enzymes: Regulation and catalysis of the poly(ADP-ribose) posttranslational modification","volume":"53","author":"Langelier","year":"2018","journal-title":"Curr. Opin. Struct. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Bondar, D., and Karpichev, Y. (2024). Poly(ADP-Ribose) Polymerase (PARP) Inhibitors for Cancer Therapy: Advances, Challenges, and Future Directions. Biomolecules, 14.","DOI":"10.3390\/biom14101269"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1017\/erm.2024.13","article-title":"PARP enzymes and mono-ADP-ribosylation: Advancing the connection from interferon-signalling to cancer biology","volume":"26","author":"Morone","year":"2024","journal-title":"Expert Rev. Mol. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41392-024-01832-1","article-title":"PARP1-DNA co-condensation: The driver of broken DNA repair","volume":"9","author":"Wei","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.tig.2024.08.009","article-title":"The complex universe of inactive PARP1","volume":"40","author":"Huang","year":"2024","journal-title":"Trends Genet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s12032-021-01570-2","article-title":"PARP1-modulated chromatin remodeling is a new target for cancer treatment","volume":"38","author":"Sinha","year":"2021","journal-title":"Med. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1007\/s10495-023-01929-y","article-title":"PARP-2 mediates cardiomyocyte aging and damage induced by doxorubicin through SIRT1 Inhibition","volume":"29","author":"Huang","year":"2024","journal-title":"Apoptosis"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"van Beek, L., McClay, \u00c9., Patel, S., Schimpl, M., Spagnolo, L., and Maia de Oliveira, T. (2021). PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22105112"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1093\/nar\/gku174","article-title":"PARP3 affects the relative contribution of homologous recombination and nonhomologous end-joining pathways","volume":"42","author":"Beck","year":"2014","journal-title":"Nucleic Acids. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2174\/1871520618666181109164645","article-title":"Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics","volume":"19","author":"Li","year":"2019","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"100251","DOI":"10.1074\/jbc.RA120.016573","article-title":"Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1","volume":"296","author":"Ryan","year":"2021","journal-title":"J. Biol. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1038\/s41467-023-37499-5","article-title":"TRABID overexpression enables synthetic lethality to PARP inhibitor via prolonging 53BP1 retention at double-strand breaks","volume":"14","author":"Ma","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41419-024-06894-1","article-title":"Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas","volume":"15","author":"Chiappa","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nature03442","article-title":"Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage","volume":"434","author":"Falck","year":"2005","journal-title":"Nature"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e2403038121","DOI":"10.1073\/pnas.2403038121","article-title":"ER-associated degradation ligase HRD1 links ER stress to DNA damage repair by modulating the activity of DNA-PKcs","volume":"121","author":"Xiang","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/s43018-021-00266-w","article-title":"The CIP2A-TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer","volume":"2","author":"Adam","year":"2021","journal-title":"Nat. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/annonc\/mdy099","article-title":"RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer","volume":"29","author":"Cruz","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3892\/ijmm.2022.5145","article-title":"Multifaceted regulation and functions of 53BP1 in NHEJ-mediated DSB repair (Review)","volume":"50","author":"Lei","year":"2022","journal-title":"Int. J. Mol. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.cell.2018.03.050","article-title":"DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity","volume":"173","author":"Gupta","year":"2018","journal-title":"Cell"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Zhao, K., Wang, X., Xue, X., Li, L., and Hu, Y. (2020). A long noncoding RNA sensitizes genotoxic treatment by attenuating ATM activation and homologous recombination repair in cancers. PLoS Biol., 18.","DOI":"10.1371\/journal.pbio.3000666"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41416-019-0565-8","article-title":"Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated\/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells","volume":"121","author":"Jette","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1002\/1878-0261.12573","article-title":"Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells","volume":"13","author":"Schoonen","year":"2019","journal-title":"Mol. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41420-025-02382-3","article-title":"Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential activity","volume":"11","author":"Masi","year":"2025","journal-title":"Cell Death Discov."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"zcaf015","DOI":"10.1093\/narcan\/zcaf015","article-title":"PARP inhibitor response is enhanced in prostate cancer when XRCC1 expression is reduced","volume":"7","author":"Goel","year":"2025","journal-title":"NAR Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1093\/nar\/gkz120","article-title":"Poly(ADP-ribosyl)ation by PARP1: Reaction mechanism and regulatory proteins","volume":"47","author":"Alemasova","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"10341","DOI":"10.1093\/nar\/gkae672","article-title":"Redundant but essential functions of PARP1 and PARP2 in DNA ligase I-independent DNA replication","volume":"52","author":"Bhandari","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1158\/1078-0432.CCR-19-2549","article-title":"EGFR Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma","volume":"26","author":"Wu","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"7430","DOI":"10.1038\/s41467-023-42850-x","article-title":"Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1\/2 and RAD51","volume":"14","author":"Tao","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1111\/cas.14565","article-title":"Synthetic lethality strategies: Beyond BRCA1\/2 mutations in pancreatic cancer","volume":"111","author":"Hu","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/carcin\/bgu211","article-title":"Enhanced non-homologous end joining contributes toward synthetic lethality of pathological RAD51C mutants with poly (ADP-ribose) polymerase","volume":"36","author":"Somyajit","year":"2015","journal-title":"Carcinogenesis"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e2322689121","DOI":"10.1073\/pnas.2322689121","article-title":"Histone ADP-ribosylation promotes resistance to PARP inhibitors by facilitating PARP1 release from DNA lesions","volume":"121","author":"Zentout","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.trecan.2024.06.008","article-title":"PARPi, BRCA, and gaps: Controversies and future research","volume":"10","author":"Dibitetto","year":"2024","journal-title":"Trends Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/annonc\/mdz012","article-title":"OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"30","author":"Robson","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejca.2023.01.031","article-title":"OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"184","author":"Robson","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","article-title":"PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer","volume":"9","author":"Pantelidou","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1158\/0008-5472.CAN-24-2531","article-title":"Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination-Deficient Breast Cancer","volume":"85","author":"Pedretti","year":"2025","journal-title":"Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/0008-5472.CAN-18-1003","article-title":"PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness","volume":"79","author":"Shen","year":"2019","journal-title":"Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1111\/cas.15961","article-title":"Combination of PARP inhibitor and CDK4\/6 inhibitor modulates cGAS\/STING-dependent therapy-induced senescence and provides \u201cone-two punch\u201d opportunity with anti-PD-L1 therapy in colorectal cancer","volume":"114","author":"Wang","year":"2023","journal-title":"Cancer Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/s43018-022-00468-w","article-title":"The cGAS-STING pathway and cancer","volume":"3","author":"Samson","year":"2022","journal-title":"Nat. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"eaay9013","DOI":"10.1126\/scitranslmed.aay9013","article-title":"cGAS-STING-mediated DNA sensing maintains CD8+ T cell stemness and promotes antitumor T cell therapy","volume":"12","author":"Li","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"eadr5861","DOI":"10.1126\/scitranslmed.adr5861","article-title":"Mitigating T cell DNA damage during PARP inhibitor treatment enhances antitumor efficacy","volume":"17","author":"Liu","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Wu, J., Shi, C., Li, H., Song, W., Huang, S., Zhang, J., Li, W., Li, Z., and Zhang, M. (2023). PARP inhibitor exerts an anti-tumor effect via LMO2 and synergizes with cisplatin in natural killer\/T cell lymphoma. BMC Med., 21.","DOI":"10.1186\/s12916-023-02904-9"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e2403782","DOI":"10.1002\/advs.202403782","article-title":"CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer","volume":"11","author":"Liu","year":"2024","journal-title":"Adv. Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1111\/jcmm.14980","article-title":"Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer","volume":"24","author":"Montero","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.annonc.2023.06.008","article-title":"Adding PARP inhibitor to an androgen-receptor signaling inhibitor in metastatic prostate cancer: What are we missing?","volume":"34","author":"Giunta","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e2205509119","DOI":"10.1073\/pnas.2205509119","article-title":"CYCLIN K down-regulation induces androgen receptor gene intronic polyadenylation, variant expression and PARP inhibitor vulnerability in castration-resistant prostate cancer","volume":"119","author":"Sun","year":"2022","journal-title":"Proc. Natl. Acad Sci. USA"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1158\/1078-0432.CCR-24-1812","article-title":"Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer","volume":"31","author":"Shah","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"eadu0847","DOI":"10.1126\/sciadv.adu0847","article-title":"Acute BRCAness induction and AR pathway blockage through CDK12\/7\/9 degradation enhances PARP inhibitor sensitivity in prostate cancer","volume":"11","author":"Gui","year":"2025","journal-title":"Sci. Adv."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1021\/acs.jmedchem.6b00990","article-title":"Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors","volume":"60","author":"Thorsell","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1038\/s41467-020-15429-z","article-title":"Differential regulation of breast cancer bone metastasis by PARP1 and PARP2","volume":"11","author":"Zuo","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.euo.2025.04.012","article-title":"Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial","volume":"8","author":"Chi","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1200\/JCO-24-02834","article-title":"Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer","volume":"43","author":"Shah","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1038\/s41591-024-03003-9","article-title":"Senaparib as first-line maintenance therapy in advanced ovarian cancer: A randomized phase 3 trial","volume":"30","author":"Wu","year":"2024","journal-title":"Nat. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1021\/acs.jmedchem.5b01498","article-title":"Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1\/2 Inhibitor, as an Anticancer Agent","volume":"59","author":"Wang","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s40265-018-1026-z","article-title":"Talazoparib: First Global Approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/cas.13947","article-title":"Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials","volume":"110","author":"Wang","year":"2019","journal-title":"Cancer Sci."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"16464","DOI":"10.1021\/acs.jmedchem.3c00865","article-title":"Advances in Development of Selective Antitumor Inhibitors That Target PARP-1","volume":"66","author":"Liu","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.canlet.2016.11.010","article-title":"Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials","volume":"386","author":"Yuan","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1200\/JCO.22.01003","article-title":"A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients with Newly Diagnosed Ovarian Cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45)","volume":"40","author":"Monk","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"115584","DOI":"10.1016\/j.ejca.2025.115584","article-title":"Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial","volume":"225","author":"Ledermann","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(19)30396-1","article-title":"Pamiparib in combination with tislelizumab in patients with advanced solid tumours: Results from the dose-escalation stage of a multicentre, open-label, phase 1a\/b trial","volume":"20","author":"Friedlander","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e03495-20","DOI":"10.1128\/mBio.03495-20","article-title":"Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses In Vitro","volume":"12","author":"Stone","year":"2021","journal-title":"mBio"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1158\/1078-0432.CCR-06-3039","article-title":"ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models","volume":"13","author":"Donawho","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"5460","DOI":"10.7150\/ijbs.113726","article-title":"JPI-547, a Dual Inhibitor of PARP\/Tankyrase, Shows Antitumor Activity Against Pancreatic Cancers with Homologous Recombination Repair Deficiency or Wnt-Addiction","volume":"21","author":"Oh","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.1016\/j.apsb.2025.09.021","article-title":"Discovery of novel radioligand [18F]AZD9574 for selective imaging of PARP1 in the CNS","volume":"15","author":"Zhou","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"21717","DOI":"10.1021\/acs.jmedchem.4c01725","article-title":"Discovery of 6-Fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD9574): A CNS-Penetrant, PARP1-Selective Inhibitor","volume":"67","author":"Johannes","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"(2022). AZD5305 More Tolerable than Earlier PARP Agents. Cancer Discov., 12, 1602.","DOI":"10.1158\/2159-8290.CD-NB2022-0039"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"118164","DOI":"10.1016\/j.ejmech.2025.118164","article-title":"Discovery of a novel benzofuran-7-carboxamide-based PARP1\/c-Met dual inhibitor for addressing c-Met amplification-mediated PARP1i acquired-resistance","volume":"300","author":"Sun","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1158\/1535-7163.MCT-22-0068","article-title":"Venadaparib Is a Novel and Selective PARP Inhibitor with Improved Physicochemical Properties, Efficacy, and Safety","volume":"22","author":"Lee","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e70576","DOI":"10.1002\/cam4.70576","article-title":"First-In-Human Dose Finding Study of Venadaparib (IDX-1197), a Potent and Selective PARP Inhibitor, in Patients with Advanced Solid Tumors","volume":"14","author":"Kim","year":"2025","journal-title":"Cancer Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1158\/0008-5472.CAN-15-3240","article-title":"The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models","volume":"76","author":"Rulten","year":"2016","journal-title":"Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"113898","DOI":"10.1016\/j.ejmech.2021.113898","article-title":"Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2","volume":"227","author":"Yu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"21380","DOI":"10.1021\/acs.jmedchem.4c02276","article-title":"Discovery of Pyrazolo[1,5,4-de]quinoxalin-2(3H)-one Derivatives as Highly Potent and Selective PARP1 Inhibitors","volume":"67","author":"Gao","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13073-024-01370-z","article-title":"The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1\/2-associated cancer models","volume":"16","author":"Staniszewska","year":"2024","journal-title":"Genome Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1158\/1078-0432.CCR-22-2630","article-title":"Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305","volume":"29","author":"Kinneer","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"4724","DOI":"10.1158\/1078-0432.CCR-22-0301","article-title":"Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper","volume":"28","author":"Illuzzi","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"14498","DOI":"10.1021\/acs.jmedchem.1c01012","article-title":"Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs","volume":"64","author":"Johannes","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Zheng, J., Li, Z., and Min, W. (2023). Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.979873"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s40265-023-01934-0","article-title":"Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options","volume":"83","author":"Garg","year":"2023","journal-title":"Drugs"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1158\/0008-5472.CAN-23-0628","article-title":"BRCAness, Homologous Recombination Deficiencies, and Synthetic Lethality","volume":"83","author":"Murai","year":"2023","journal-title":"Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/nature06548","article-title":"Resistance to therapy caused by intragenic deletion in BRCA2","volume":"451","author":"Edwards","year":"2008","journal-title":"Nature"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s10549-021-06258-9","article-title":"Double heterozygotes of BRCA1\/BRCA2 and mismatch repair gene pathogenic variants: Case series and clinical implications","volume":"188","author":"Laish","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/oncolo\/oyae082","article-title":"Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: A molecular tumor board case report and a cBioPortal comprehensive analysis","volume":"29","author":"Repetto","year":"2024","journal-title":"Oncologist"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e9172","DOI":"10.15252\/emmm.201809172","article-title":"A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation","volume":"10","author":"Cruz","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1038\/s41467-018-05564-z","article-title":"Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma","volume":"9","author":"Kondrashova","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1038\/s41418-020-0521-4","article-title":"53BP1 loss rescues embryonic lethality but not genomic instability of BRCA1 total knockout mice","volume":"27","author":"Chen","year":"2020","journal-title":"Cell Death Differ."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1158\/0008-5472.CAN-21-2409","article-title":"Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification","volume":"82","author":"Pellegrino","year":"2022","journal-title":"Cancer Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"103882","DOI":"10.1016\/j.dnarep.2025.103882","article-title":"Toxoplasma gondii RAD51 recombinase is required to overcome DNA replication stress and its inactivation leads to bradyzoite differentiation","volume":"152","author":"Cristaldi","year":"2025","journal-title":"DNA Repair"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41594-024-01381-9","article-title":"Shieldin and CST co-orchestrate DNA polymerase-dependent tailed-end joining reactions independently of 53BP1-governed repair pathway choice","volume":"32","author":"King","year":"2025","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/s41594-023-01074-9","article-title":"Dynamics of the DYNLL1-MRE11 complex regulate DNA end resection and recruitment of Shieldin to DSBs","volume":"30","author":"Swift","year":"2023","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.molcel.2013.08.030","article-title":"Phosphorylation-dependent assembly and coordination of the DNA damage checkpoint apparatus by Rad4(TopBP1)","volume":"51","author":"Qu","year":"2013","journal-title":"Mol. Cell"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1016\/j.molcel.2025.05.010","article-title":"BRCA2 C-terminal clamp restructures RAD51 dimers to bind B-DNA for replication fork stability","volume":"85","author":"Longo","year":"2025","journal-title":"Mol. Cell"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e2300483","DOI":"10.1200\/PO.23.00483","article-title":"Combining Homologous Recombination-Deficient Testing and Functional RAD51 Analysis Enhances the Prediction of Poly(ADP-Ribose) Polymerase Inhibitor Sensitivity","volume":"8","author":"Korsholm","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.molcel.2018.12.010","article-title":"BRCA1 Haploinsufficiency Is Masked by RNF168-Mediated Chromatin Ubiquitylation","volume":"73","author":"Zong","year":"2019","journal-title":"Mol. Cell"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/j.ccell.2024.10.015","article-title":"Elucidating acquired PARP inhibitor resistance in advanced prostate cancer","volume":"42","author":"Seed","year":"2024","journal-title":"Cancer Cell"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00176","article-title":"Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting from Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations","volume":"2","author":"Carneiro","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","article-title":"BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma","volume":"9","author":"Lin","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"10596","DOI":"10.1038\/s41467-024-54978-5","article-title":"DTX3L-mediated TIRR nuclear export and degradation regulates DNA repair pathway choice and PARP inhibitor sensitivity","volume":"15","author":"Ye","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.7150\/jca.66020","article-title":"Inducing Synergistic DNA Damage by TRIP13 and PARP1 Inhibitors Provides a Potential Treatment for Hepatocellular Carcinoma","volume":"13","author":"Xu","year":"2022","journal-title":"J. Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev-genet-110410-132435","article-title":"Double-strand break end resection and repair pathway choice","volume":"45","author":"Symington","year":"2011","journal-title":"Annu. Rev. Genet."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"115452","DOI":"10.1016\/j.celrep.2025.115452","article-title":"DSCC1 restrains 53BP1\/RIF1 signaling at DNA double-strand breaks to promote homologous recombination repair","volume":"44","author":"Tian","year":"2025","journal-title":"Cell Rep."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"10361","DOI":"10.1038\/s41467-025-65329-3","article-title":"53BP1-RIF1 and DNA-PKcs show distinct genetic interactions with diverse chromosomal break repair outcomes","volume":"16","author":"Makins","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nsmb.2212","article-title":"Mre11 regulates CtIP-dependent double-strand break repair by interaction with CDK2","volume":"19","author":"Buis","year":"2012","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1080\/15384101.2015.1078020","article-title":"Cdk5 promotes DNA replication stress checkpoint activation through RPA-32 phosphorylation, and impacts on metastasis free survival in breast cancer patients","volume":"14","author":"Chiker","year":"2015","journal-title":"Cell Cycle"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00018-011-0811-6","article-title":"The impact of cyclin-dependent kinase 5 depletion on poly(ADP-ribose) polymerase activity and responses to radiation","volume":"69","author":"Bolin","year":"2012","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1158\/0008-5472.CAN-13-2541","article-title":"Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1\/2 inhibitor sensitivity","volume":"74","author":"Bajrami","year":"2014","journal-title":"Cancer Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1038\/s41467-024-51229-5","article-title":"CDK12 controls transcription at damaged genes and prevents MYC-induced transcription-replication conflicts","volume":"15","author":"Curti","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"216820","DOI":"10.1016\/j.canlet.2024.216820","article-title":"CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer","volume":"589","author":"Orhan","year":"2024","journal-title":"Cancer Lett."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1038\/s41467-019-10993-5","article-title":"Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma","volume":"10","author":"Ning","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Tian, C., Wei, Y., Li, J., Huang, Z., Wang, Q., Lin, Y., Lv, X., Chen, Y., Fan, Y., and Sun, P. (2022). A Novel CDK4\/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin Treatment in Breast and Ovarian Cancer. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23052892"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13046-021-01930-w","article-title":"Efficacy and mechanism of the combination of PARP and CDK4\/6 inhibitors in the treatment of triple-negative breast cancer","volume":"40","author":"Zhu","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.20131939","article-title":"CtIP-mediated resection is essential for viability and can operate independently of BRCA1","volume":"211","author":"Polato","year":"2014","journal-title":"J. Exp. Med."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Campillo-Marcos, I., Monte-Serrano, E., Navarro-Carrasco, E., Garc\u00eda-Gonz\u00e1lez, R., and Lazo, P.A. (2021). Lysine Methyltransferase Inhibitors Impair H4K20me2 and 53BP1 Foci in Response to DNA Damage in Sarcomas, a Synthetic Lethality Strategy. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.715126"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Hong, R., Ma, F., Zhang, W., Yu, X., Li, Q., Luo, Y., Zhu, C., Jiang, W., and Xu, B. (2016). 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells. BMC Cancer, 16, Erratum in BMC Cancer\u00a02016, 16, 925.","DOI":"10.1186\/s12885-016-2970-1"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/cas.13477","article-title":"Acquired resistance of phosphatase and tensin homolog-deficient cells to poly(ADP-ribose) polymerase inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1 overexpression","volume":"109","author":"Wang","year":"2018","journal-title":"Cancer Sci."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"6676","DOI":"10.1038\/s41467-024-50999-2","article-title":"53BP1 loss elicits cGAS-STING-dependent antitumor immunity in ovarian and pancreatic cancer","volume":"15","author":"Sun","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s43018-024-00902-1","article-title":"Targeting BRCA1-deficient PARP inhibitor-resistant cells with nickases reveals nick resection as a cancer vulnerability","volume":"6","author":"Whalen","year":"2025","journal-title":"Nat. Cancer"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-018-0324-7","article-title":"53BP1-RIF1-shieldin counteracts DSB resection through CST- and Pol\u03b1-dependent fill-in","volume":"560","author":"Mirman","year":"2018","journal-title":"Nature"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"gkaf554","DOI":"10.1093\/nar\/gkaf554","article-title":"The inflammasome sensor NLRP3 interacts with REV7 to maintain genome integrity through homologous recombination","volume":"53","author":"Burlet","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41556-019-0442-y","article-title":"TRIP13 regulates DNA repair pathway choice through REV7 conformational change","volume":"22","author":"Clairmont","year":"2020","journal-title":"Nat. Cell Biol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41586-018-0340-7","article-title":"The shieldin complex mediates 53BP1-dependent DNA repair","volume":"560","author":"Noordermeer","year":"2018","journal-title":"Nature"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.molcel.2022.01.025","article-title":"RIF1 acts in DNA repair through phosphopeptide recognition of 53BP1","volume":"82","author":"Setiaputra","year":"2022","journal-title":"Mol. Cell"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Muvaffak, A., and Coleman, K.G. (2024). PARP inhibitor synthetic lethality in ATM biallelic mutant cancer cell lines is associated with BRCA1\/2 and RAD51 downregulation. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1380633"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1756-9966-32-95","article-title":"ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition","volume":"32","author":"Prodosmo","year":"2013","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Burdova, K., Storchova, R., Palek, M., and Macurek, L. (2019). WIP1 Promotes Homologous Recombination and Modulates Sensitivity to PARP Inhibitors. Cells, 8.","DOI":"10.3390\/cells8101258"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41580-025-00841-4","article-title":"Mechanisms and regulation of DNA end resection in the maintenance of genome stability","volume":"26","author":"Ceccaldi","year":"2025","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.cell.2023.11.022","article-title":"Metabolic regulation of homologous recombination repair by MRE11 lactylation","volume":"187","author":"Chen","year":"2024","journal-title":"Cell"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1158\/2767-9764.CRC-23-0166","article-title":"DNA2 Nuclease Inhibition Confers Synthetic Lethality in Cancers with Mutant p53 and Synergizes with PARP Inhibitors","volume":"3","author":"Graves","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1126\/science.adt3034","article-title":"CTC1-STN1-TEN1 controls DNA break repair pathway choice via DNA end resection blockade","volume":"388","author":"Rogers","year":"2025","journal-title":"Science"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"102337","DOI":"10.1016\/j.tranon.2025.102337","article-title":"Targeting FEN1\/EXO1 to enhance efficacy of PARP inhibition in triple-negative breast cancer","volume":"54","author":"Frederick","year":"2025","journal-title":"Transl. Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"gkaf544","DOI":"10.1093\/nar\/gkaf544","article-title":"USP37 counteracts HLTF to protect damaged replication forks and promote survival of BRCA1-deficient cells and PARP inhibitor resistance","volume":"53","author":"Tang","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"7834","DOI":"10.1093\/nar\/gkaa559","article-title":"RADX condenses single-stranded DNA to antagonize RAD51 loading","volume":"48","author":"Zhang","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41467-021-27940-y","article-title":"Deciphering the mechanism of processive ssDNA digestion by the Dna2-RPA ensemble","volume":"13","author":"Shen","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1016\/j.molcel.2025.08.017","article-title":"RAD51 is chromatin enriched and targetable in BRCA1-deficient cells","volume":"85","author":"Peng","year":"2025","journal-title":"Mol. Cell"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"114205","DOI":"10.1016\/j.celrep.2024.114205","article-title":"Loss of POLE3-POLE4 unleashes replicative gap accumulation upon treatment with PARP inhibitors","volume":"43","author":"Hill","year":"2024","journal-title":"Cell Rep."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"102443","DOI":"10.1016\/j.redox.2022.102443","article-title":"Redox regulation of RAD51 Cys319 and homologous recombination by peroxiredoxin 1","volume":"56","author":"Skoko","year":"2022","journal-title":"Redox Biol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.molcel.2018.11.003","article-title":"The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers","volume":"73","author":"Marzio","year":"2019","journal-title":"Mol. Cell"},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Moustafa, D., Elwahed, M.R.A., Elsaid, H.H., and Parvin, J.D. (2021). Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells. PLoS ONE, 16.","DOI":"10.1101\/2020.06.09.142026"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1111\/cas.14201","article-title":"Depletion of DNA damage binding protein 2 sensitizes triple-negative breast cancer cells to poly ADP-ribose polymerase inhibition by destabilizing Rad51","volume":"110","author":"Zhao","year":"2019","journal-title":"Cancer Sci."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"e2307793120","DOI":"10.1073\/pnas.2307793120","article-title":"A small-molecule inhibitor of TopBP1 exerts anti-MYC activity and synergy with PARP inhibitors","volume":"120","author":"Lin","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1083\/jcb.201507042","article-title":"TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity","volume":"212","author":"Moudry","year":"2016","journal-title":"J. Cell Biol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"zcaf013","DOI":"10.1093\/narcan\/zcaf013","article-title":"Synergistic enhancement of PARP inhibition via small molecule UNI66-mediated suppression of BRD4-dependent transcription of RAD51 and CtIP","volume":"7","author":"Amarsanaa","year":"2025","journal-title":"NAR Cancer"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/jcmm.17683","article-title":"Synergistic effect of PARP inhibitor and BRD4 inhibitor in multiple models of ovarian cancer","volume":"27","author":"Huang","year":"2023","journal-title":"J. Cell Mol. Med."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.7150\/ijbs.34162","article-title":"BRD4 Inhibitor AZD5153 Suppresses the Proliferation of Colorectal Cancer Cells and Sensitizes the Anticancer Effect of PARP Inhibitor","volume":"15","author":"Zhang","year":"2019","journal-title":"Int. J. Biol. Sci."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s42003-025-07804-7","article-title":"Targeting FOXP1 phase separation in small cell lung cancer mechanisms of chemotherapy resistance","volume":"8","author":"Tang","year":"2025","journal-title":"Commun. Biol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41420-022-00946-1","article-title":"The cancer\/testis antigen HORMAD1 mediates epithelial-mesenchymal transition to promote tumor growth and metastasis by activating the Wnt\/\u03b2-catenin signaling pathway in lung cancer","volume":"8","author":"Liu","year":"2022","journal-title":"Cell Death Discov."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"105348","DOI":"10.1016\/j.jbc.2023.105348","article-title":"The cancer testes antigen, HORMAD1, limits genomic instability in cancer cells by protecting stalled replication forks","volume":"299","author":"Herrera","year":"2023","journal-title":"J. Biol. Chem."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"10879","DOI":"10.1093\/nar\/gkw921","article-title":"Roles for APRIN (PDS5B) in homologous recombination and in ovarian cancer prediction","volume":"44","author":"Couturier","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1080\/15384047.2018.1529126","article-title":"Discovery of a novel DNA polymerase inhibitor and characterization of its antiproliferative properties","volume":"20","author":"Mishra","year":"2019","journal-title":"Cancer Biol. Ther."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1038\/s41467-024-48715-1","article-title":"H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours","volume":"15","author":"Dibitetto","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"6343","DOI":"10.1038\/s41467-024-50673-7","article-title":"Nucleolytic processing of abasic sites underlies PARP inhibitor hypersensitivity in ALC1-deficient BRCA mutant cancer cells","volume":"15","author":"Ramakrishnan","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/ncb3626","article-title":"EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation","volume":"19","author":"Rondinelli","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nature18325","article-title":"Replication fork stability confers chemoresistance in BRCA-deficient cells","volume":"535","author":"Callen","year":"2016","journal-title":"Nature"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"eabf9441","DOI":"10.1126\/sciadv.abf9441","article-title":"MRE11-dependent instability in mitochondrial DNA fork protection activates a cGAS immune signaling pathway","volume":"7","author":"Luzwick","year":"2021","journal-title":"Sci. Adv."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"101034","DOI":"10.1016\/j.mcpro.2025.101034","article-title":"Multi-omics Characterization of Acquired Olaparib Resistance in BRCA1 and BRCA2 Mutant Breast Cancer Cell Lines","volume":"24","author":"Mullari","year":"2025","journal-title":"Mol. Cell Proteom."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/15384047.2019.1579955","article-title":"Clinical importance of FANCD2, BRIP1, BRCA1, BRCA2 and FANCF expression in ovarian carcinomas","volume":"20","author":"Rzepecka","year":"2019","journal-title":"Cancer Biol. Ther."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"eadu0437","DOI":"10.1126\/sciadv.adu0437","article-title":"Mechanism of DNA replication fork breakage and PARP1 hyperactivation during replication catastrophe","volume":"11","author":"Ortega","year":"2025","journal-title":"Sci. Adv."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/s41388-025-03409-w","article-title":"DNMT1 is required for efficient DSB repair and maintenance of replication fork stability, and its loss reverses resistance to PARP inhibitors in cancer cells","volume":"44","author":"Wu","year":"2025","journal-title":"Oncogene"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1016\/j.molcel.2024.10.016","article-title":"Profound synthetic lethality between SMARCAL1 and FANCM","volume":"84","author":"Feng","year":"2024","journal-title":"Mol. Cell"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"8008","DOI":"10.1093\/nar\/gkac583","article-title":"Strand annealing and motor driven activities of SMARCAL1 and ZRANB3 are stimulated by RAD51 and the paralog complex","volume":"50","author":"Halder","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.molcel.2019.05.026","article-title":"EXD2 Protects Stressed Replication Forks and Is Required for Cell Viability in the Absence of BRCA1\/2","volume":"75","author":"Nieminuszczy","year":"2019","journal-title":"Mol. Cell"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"8320","DOI":"10.1093\/nar\/gkae546","article-title":"MRNIP limits ssDNA gaps during replication stress","volume":"52","author":"Bennett","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.molcel.2017.06.023","article-title":"RADX Promotes Genome Stability and Modulates Chemosensitivity by Regulating RAD51 at Replication Forks","volume":"67","author":"Dungrawala","year":"2017","journal-title":"Mol. Cell"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/s41589-024-01611-7","article-title":"UFL1 triggers replication fork degradation by MRE11 in BRCA1\/2-deficient cells","volume":"20","author":"Tian","year":"2024","journal-title":"Nat. Chem. Biol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"107312","DOI":"10.1016\/j.jbc.2024.107312","article-title":"PTIP UFMylation promotes replication fork degradation in BRCA1-deficient cells","volume":"300","author":"Tan","year":"2024","journal-title":"J. Biol. Chem."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41586-025-09414-z","article-title":"NASP modulates histone turnover to drive PARP inhibitor resistance","volume":"645","author":"Moser","year":"2025","journal-title":"Nature"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12943-025-02355-1","article-title":"Clinical approaches to overcome PARP inhibitor resistance","volume":"24","author":"Zou","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"189267","DOI":"10.1016\/j.bbcan.2025.189267","article-title":"An overview of BAP1 biological functions and current therapeutics","volume":"1880","author":"Elsayed","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"101076","DOI":"10.1016\/j.neo.2024.101076","article-title":"The role of glycolysis in tumorigenesis: From biological aspects to therapeutic opportunities","volume":"58","author":"Cordani","year":"2024","journal-title":"Neoplasia"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12964-025-02047-9","article-title":"Impact of glycolysis enzymes and metabolites in regulating DNA damage repair in tumorigenesis and therapy","volume":"23","author":"Sun","year":"2025","journal-title":"Cell Commun. Signal."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.freeradbiomed.2020.11.007","article-title":"NAD+ depletion radiosensitizes 2-DG-treated glioma cells by abolishing metabolic adaptation","volume":"162","author":"Shi","year":"2021","journal-title":"Free Radic. Biol. Med."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"113988","DOI":"10.1016\/j.bcp.2020.113988","article-title":"3-Bromopyruvate regulates the status of glycolysis and BCNU sensitivity in human hepatocellular carcinoma cells","volume":"177","author":"Sun","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"ref_198","first-page":"4977","article-title":"3-Bromopyruvate inhibits pancreatic tumor growth by stalling glycolysis, and dismantling mitochondria in a syngeneic mouse model","volume":"12","author":"Roy","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1158\/1078-0432.CCR-23-0200","article-title":"Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models","volume":"29","author":"Collins","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"130117","DOI":"10.1016\/j.bmcl.2025.130117","article-title":"Discovery of dual PARP\/NAMPT inhibitors for the treatment of BRCA wild-type triple-negative breast cancer","volume":"120","author":"Mao","year":"2025","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"5948","DOI":"10.1158\/0008-5472.CAN-14-0809","article-title":"Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption","volume":"74","author":"Chan","year":"2014","journal-title":"Cancer Res."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s42003-025-09223-0","article-title":"RAS\/PI3K pathway mutations sensitise epithelial ovarian cancer cells to a PARP\/NAMPT inhibitor combination","volume":"9","author":"Gruet","year":"2025","journal-title":"Commun. Biol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1038\/s41375-019-0683-6","article-title":"Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia","volume":"34","author":"Somers","year":"2020","journal-title":"Leukemia"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"897","DOI":"10.7150\/ijbs.81609","article-title":"An Overview: The Diversified Role of Mitochondria in Cancer Metabolism","volume":"19","author":"Liu","year":"2023","journal-title":"Int. J. Biol. Sci."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1158\/1078-0432.CCR-17-3070","article-title":"Oxidative Phosphorylation as an Emerging Target in Cancer Therapy","volume":"24","author":"Ashton","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41392-020-00354-w","article-title":"NAD+ metabolism, stemness, the immune response, and cancer","volume":"6","author":"Navas","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.cmet.2018.06.002","article-title":"Etomoxir Actions on Regulatory and Memory T Cells Are Independent of Cpt1a-Mediated Fatty Acid Oxidation","volume":"28","author":"Raud","year":"2018","journal-title":"Cell Metab."},{"key":"ref_208","doi-asserted-by":"crossref","unstructured":"Clausing, M., William, D., Preussler, M., Biedermann, J., Gr\u00fctzmann, K., Richter, S., Buchholz, F., Temme, A., Schr\u00f6ck, E., and Klink, B. (2022). Different Effects of RNAi-Mediated Downregulation or Chemical Inhibition of NAMPT in an Isogenic IDH Mutant and Wild-Type Glioma Cell Model. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23105787"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"6755","DOI":"10.1038\/s41467-024-50861-5","article-title":"Histone-methyltransferase KMT2D deficiency impairs the Fanconi anemia\/BRCA pathway upon glycolytic inhibition in squamous cell carcinoma","volume":"15","author":"Liu","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.3892\/or.2017.5491","article-title":"Co-treatment of breast cancer cells with pharmacologic doses of 2-deoxy-D-glucose and metformin: Starving tumors","volume":"37","author":"Wokoun","year":"2017","journal-title":"Oncol. Rep."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"117414","DOI":"10.1016\/j.bcp.2025.117414","article-title":"Mechanistic insights into P-glycoprotein-driven transport of anti-cancer PARP inhibitors","volume":"242","author":"Kozarich","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"ref_212","doi-asserted-by":"crossref","unstructured":"Makrecka-Kuka, M., Vasiljeva, J., Dimitrijevs, P., and Arsenyan, P. (2022). Olaparib Conjugates with Selenopheno[3,2-c]quinolinone Inhibit PARP1 and Reverse ABCB1-Related Multidrug Resistance. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14122571"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1007\/s00432-022-04503-2","article-title":"Interactive webtool for analyzing drug sensitivity and resistance associated with genetic signatures of cancer cell lines","volume":"149","author":"Boeschen","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"17588359231208674","DOI":"10.1177\/17588359231208674","article-title":"The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models","volume":"15","author":"Ho","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/s41467-019-09312-9","article-title":"Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer","volume":"10","author":"Christie","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12943-024-02025-8","article-title":"PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancer","volume":"23","author":"Liu","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"101028","DOI":"10.1016\/j.drup.2023.101028","article-title":"Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor","volume":"73","author":"Teng","year":"2024","journal-title":"Drug Resist. Updates"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/bjc.2016.203","article-title":"ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells","volume":"115","author":"Vaidyanathan","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"e2400140","DOI":"10.1002\/advs.202400140","article-title":"KAT6A Condensates Impair PARP1 Trapping of PARP Inhibitors in Ovarian Cancer","volume":"11","author":"Zhan","year":"2024","journal-title":"Adv. Sci."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1038\/s41467-018-03917-2","article-title":"Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance","volume":"9","author":"Pettitt","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.ccell.2018.05.008","article-title":"Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality","volume":"33","author":"Gogola","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41419-023-06303-z","article-title":"Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer","volume":"15","author":"Zhu","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"e07904","DOI":"10.1002\/advs.202507904","article-title":"Targeting HDAC and PARP Enhances STING-Dependent Antitumor Immunity in STING-Deficient Tumor","volume":"12","author":"Mao","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1158\/1078-0432.CCR-22-3897","article-title":"A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma","volume":"29","author":"Ramos","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.biopha.2018.01.045","article-title":"Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells","volume":"99","author":"Marijon","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s13046-020-01728-2","article-title":"The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer","volume":"39","author":"Ma","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"e18342","DOI":"10.1111\/jcmm.18342","article-title":"New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma","volume":"28","author":"Meneceur","year":"2024","journal-title":"J. Cell. Mol. Med."},{"key":"ref_228","doi-asserted-by":"crossref","unstructured":"Drzewiecka, M., Gajos-Michniewicz, A., Hoser, G., Ja\u015bniak, D., Barszczewska-Pietraszek, G., Sitarek, P., Czarny, P., Piekarski, J., Radek, M., and Czy\u017c, M. (2023). Histone Deacetylases (HDAC) Inhibitor-Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor. Genes, 14.","DOI":"10.3390\/genes14061295"},{"key":"ref_229","doi-asserted-by":"crossref","unstructured":"Valdez, B.C., Tsimberidou, A.M., Yuan, B., Baysal, M.A., Chakraborty, A., Andersen, C.R., and Andersson, B.S. (2024). Synergistic Cytotoxicity of Histone Deacetylase and Poly-ADP Ribose Polymerase Inhibitors and Decitabine in Breast and Ovarian Cancer Cells: Implications for Novel Therapeutic Combinations. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25179241"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13046-018-0810-7","article-title":"PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1\/BRCA1 DNA damage repair complex in prostate cancer cells","volume":"37","author":"Yin","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.1158\/1078-0432.CCR-23-3785","article-title":"Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors","volume":"30","author":"Chou","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00210-022-02375-4","article-title":"Novel combination treatment of CDK 4\/6 inhibitors with PARP inhibitors in triple negative breast cancer cells","volume":"396","author":"Ozman","year":"2023","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"117367","DOI":"10.1016\/j.ejmech.2025.117367","article-title":"Design, synthesis and biological evaluation of dual CDK9\/PARP inhibitors for the treatment of cancer","volume":"287","author":"Huang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_234","doi-asserted-by":"crossref","unstructured":"Bono, A., La Monica, G., Alamia, F., Mingoia, F., Gentile, C., Peri, D., Lauria, A., and Martorana, A. (2023). In Silico Mixed Ligand\/Structure-Based Design of New CDK-1\/PARP-1 Dual Inhibitors as Anti-Breast Cancer Agents. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241813769"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41523-021-00312-x","article-title":"Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition","volume":"7","author":"Aziz","year":"2021","journal-title":"npj Breast Cancer"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.celrep.2016.10.077","article-title":"CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer","volume":"17","author":"Johnson","year":"2016","journal-title":"Cell Rep."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1158\/1535-7163.MCT-15-0660","article-title":"A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition","volume":"15","author":"Alagpulinsa","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"100962","DOI":"10.1016\/j.drup.2023.100962","article-title":"Current therapy and drug resistance in metastatic castration-resistant prostate cancer","volume":"68","author":"Cai","year":"2023","journal-title":"Drug Resist. Updates"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.euo.2023.07.013","article-title":"Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis","volume":"7","author":"Messina","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.euo.2024.11.011","article-title":"Recent and Future Developments in the Use of Poly (ADP-ribose) Polymerase Inhibitors for Prostate Cancer","volume":"8","author":"Zacchi","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"102623","DOI":"10.1016\/j.ctrv.2023.102623","article-title":"Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials","volume":"120","author":"Iannantuono","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"eaam7479","DOI":"10.1126\/scisignal.aam7479","article-title":"Androgen receptor inhibitor-induced \u201cBRCAness\u201d and PARP inhibition are synthetically lethal for castration-resistant prostate cancer","volume":"10","author":"Li","year":"2017","journal-title":"Sci. Signal."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-022-01042-7","article-title":"Targeting signaling pathways in prostate cancer: Mechanisms and clinical trials","volume":"7","author":"He","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1158\/0008-5472.CAN-24-4096","article-title":"A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition","volume":"85","author":"Ye","year":"2025","journal-title":"Cancer Res."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s40265-024-02071-y","article-title":"Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer","volume":"84","author":"Kostos","year":"2024","journal-title":"Drugs"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"17588359241258443","DOI":"10.1177\/17588359241258443","article-title":"Androgen receptor, PARP signaling, and tumor microenvironment: The \u2018perfect triad\u2019 in prostate cancer?","volume":"16","author":"Garofoli","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41391-024-00924-x","article-title":"Talazoparib plus enzalutamide versus olaparib plus abiraterone acetate and niraparib plus abiraterone acetate for metastatic castration-resistant prostate cancer: A matching-adjusted indirect comparison","volume":"28","author":"Castro","year":"2025","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): A randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1158\/0008-5472.CAN-22-1535","article-title":"BRCA1-Dependent and Independent Recruitment of PALB2-BRCA2-RAD51 in the DNA Damage Response and Cancer","volume":"82","author":"Foo","year":"2022","journal-title":"Cancer Res."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1016\/j.molcel.2025.07.003","article-title":"PALB2 and 53BP1 govern post-resection homologous recombination DNA repair","volume":"85","author":"Wang","year":"2025","journal-title":"Mol. Cell"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.annonc.2024.01.003","article-title":"Longitudinal profiling identifies co-occurring BRCA1\/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer","volume":"35","author":"Raghunandan","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"6685","DOI":"10.1038\/s41467-025-61811-0","article-title":"Mechanism of Rad51 filament formation by Rad52 and Rad55-Rad57 in homologous recombination","volume":"16","author":"Deveryshetty","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"7834","DOI":"10.1038\/s41467-023-43677-2","article-title":"Mechanisms of synthetic lethality between BRCA1\/2 and 53BP1 deficiencies and DNA polymerase theta targeting","volume":"14","author":"Ronson","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1158\/1541-7786.MCR-22-1035","article-title":"Simultaneous Targeting of DNA Polymerase Theta and PARP1 or RAD52 Triggers Dual Synthetic Lethality in Homologous Recombination-Deficient Leukemia Cells","volume":"21","author":"Toma","year":"2023","journal-title":"Mol. Cancer Res."},{"key":"ref_256","doi-asserted-by":"crossref","unstructured":"Barszczewska-Pietraszek, G., Czarny, P., Drzewiecka, M., B\u0142aszczyk, M., Radek, M., Synowiec, E., Wigner-Jeziorska, P., Sitarek, P., Szemraj, J., and Skorski, T. (2024). Pol\u03b8 Inhibitor (ART558) Demonstrates a Synthetic Lethal Effect with PARP and RAD52 Inhibitors in Glioblastoma Cells. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25179134"},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1093\/eurheartj\/ehab249","article-title":"STING, a cytosolic DNA sensor, plays a critical role in atherogenesis: A link between innate immunity and chronic inflammation caused by lifestyle-related diseases","volume":"42","author":"Pham","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1038\/s41467-025-57257-z","article-title":"PARP inhibitor radiosensitization enhances anti-PD-L1 immunotherapy through stabilizing chemokine mRNA in small cell lung cancer","volume":"16","author":"Ran","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"114712","DOI":"10.1016\/j.biopha.2023.114712","article-title":"Targeting PARP for the optimal immunotherapy efficiency in gynecologic malignancies","volume":"162","author":"Li","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"e005627","DOI":"10.1136\/jitc-2022-005627","article-title":"STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer","volume":"11","author":"Ding","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"e03866","DOI":"10.1002\/advs.202503866","article-title":"Prickle4 Drives Microenvironmental Remodeling and Resistance to Parp Inhibition in IDH-Mutant Glioma","volume":"13","author":"Yang","year":"2026","journal-title":"Adv. Sci."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"216676","DOI":"10.1016\/j.canlet.2024.216676","article-title":"PARP inhibitor plus radiotherapy reshape the immune suppressive microenvironment and potentiate the efficacy of immune checkpoint inhibitors in tumors with IDH1 mutation","volume":"586","author":"Hu","year":"2024","journal-title":"Cancer Lett."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.7150\/ijbs.79654","article-title":"Loss of HRD functional phenotype impedes immunotherapy and can be reversed by HDAC inhibitor in ovarian cancer","volume":"19","author":"Yang","year":"2023","journal-title":"Int. J. Biol. Sci."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.7150\/thno.96163","article-title":"Single-cell analyses reveal evolution mimicry during the specification of breast cancer subtype","volume":"14","author":"Gao","year":"2024","journal-title":"Theranostics"},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"115329","DOI":"10.1016\/j.ejca.2025.115329","article-title":"Immunotherapy and PARP inhibitors as first-line treatment in endometrial cancer: A systematic review and network meta-analysis","volume":"220","author":"Villacampa","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"e173757","DOI":"10.1172\/JCI173757","article-title":"FGFR3-induced Y158 PARP1 phosphorylation promotes PARP inhibitor resistance via BRG1\/MRE11-mediated DNA repair in breast cancer models","volume":"135","author":"Chen","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jtho.2024.10.021","article-title":"Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients with SLFN11 Positive Extensive-Stage SCLC: S1929","volume":"20","author":"Karim","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"101169","DOI":"10.1016\/j.redox.2019.101169","article-title":"Nitric oxide-donor\/PARP-inhibitor combination: A new approach for sensitization to ionizing radiation","volume":"24","author":"Wilson","year":"2019","journal-title":"Redox Biol."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1038\/s41388-018-0130-6","article-title":"PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53","volume":"37","author":"Liu","year":"2018","journal-title":"Oncogene"},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1182\/bloodadvances.2021004638","article-title":"PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome","volume":"5","author":"Kontandreopoulou","year":"2021","journal-title":"Blood Adv."},{"key":"ref_271","doi-asserted-by":"crossref","unstructured":"Rivero Belench\u00f3n, I., Congregado Ruiz, C.B., Saez, C., Osman Garc\u00eda, I., and Medina L\u00f3pez, R.A. (2023). Parp Inhibitors and Radiotherapy: A New Combination for Prostate Cancer (Systematic Review). Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241612978"},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S2468-1253(17)30012-2","article-title":"Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: A phase 1b study","volume":"2","author":"Czito","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11060-015-1733-1","article-title":"Veliparib in combination with whole brain radiation therapy in patients with brain metastases: Results of a phase 1 study","volume":"122","author":"Mehta","year":"2015","journal-title":"J. Neurooncol."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1158\/1535-7163.MCT-19-0520","article-title":"PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation","volume":"18","author":"Michmerhuizen","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_275","doi-asserted-by":"crossref","unstructured":"Softah, A., Alotaibi, M.R., Alhoshani, A.R., Saleh, T., Alhazzani, K., Almutairi, M.M., AlRowis, R., Alshehri, S., Albekairy, N.A., and Harada, H. (2023). The Combination of Radiation with PARP Inhibition Enhances Senescence and Sensitivity to the Senolytic, Navitoclax, in Triple Negative Breast Tumor Cells. Biomedicines, 11.","DOI":"10.3390\/biomedicines11113066"},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"djw229","DOI":"10.1093\/jnci\/djw229","article-title":"Rad51 Degradation: Role in Oncolytic Virus\u2014Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma","volume":"109","author":"Ning","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13045-024-01554-5","article-title":"Identification of restrictive molecules involved in oncolytic virotherapy using genome-wide CRISPR screening","volume":"17","author":"Zhong","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/j.molcel.2025.06.004","article-title":"Isoform-specific function of NSD3 in DNA replication stress confers resistance to PARP inhibitors in prostate cancer","volume":"85","author":"Zhu","year":"2025","journal-title":"Mol. Cell"},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"115329","DOI":"10.1016\/j.bcp.2022.115329","article-title":"A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer","volume":"206","author":"Li","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"116405","DOI":"10.1016\/j.ejmech.2024.116405","article-title":"High affinity and low PARP-trapping benzimidazole derivatives as a potential warhead for PARP1 degraders","volume":"271","author":"Peng","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41698-023-00411-x","article-title":"ALDH1A1 promotes PARP inhibitor resistance by enhancing retinoic acid receptor-mediated DNA polymerase \u03b8 expression","volume":"7","author":"Lavudi","year":"2023","journal-title":"npj Precis. Oncol."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1038\/s41467-021-23463-8","article-title":"Pol\u03b8 inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance","volume":"12","author":"Zatreanu","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"e230270","DOI":"10.1002\/advs.202302705","article-title":"NAT10\/ac4C\/FOXP1 Promotes Malignant Progression and Facilitates Immunosuppression by Reprogramming Glycolytic Metabolism in Cervical Cancer","volume":"10","author":"Chen","year":"2023","journal-title":"Adv. Sci."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"101241","DOI":"10.1016\/j.drup.2025.101241","article-title":"Targeting NAT10 attenuates homologous recombination via destabilizing DNA:RNA hybrids and overcomes PARP inhibitor resistance in cancers","volume":"81","author":"Xu","year":"2025","journal-title":"Drug Resist. Updates"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/3\/355\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T05:11:20Z","timestamp":1773465080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/3\/355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":284,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["pharmaceutics18030355"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18030355","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]}}}